上尿路上皮癌治疗模式的演变。

IF 5.6 2区医学 Q1 UROLOGY & NEPHROLOGY

European urology focus Pub Date : 2025-07-08 DOI:10.1016/j.euf.2025.06.013

Saad O Atiq, Matthew D Galsky

{"title":"上尿路上皮癌治疗模式的演变。","authors":"Saad O Atiq, Matthew D Galsky","doi":"10.1016/j.euf.2025.06.013","DOIUrl":null,"url":null,"abstract":"Treatment decisions for patients with upper tract urothelial carcinoma (UTUC) require individualized assessments that weigh tumor characteristics, patient factors, and the evidence available. Adjuvant immune checkpoint blockade represents a significant advance in UTUC management, particularly for patients who are ineligible for cisplatin and those with residual disease after neoadjuvant therapy.","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Evolving Treatment Paradigm for Upper Tract Urothelial Carcinoma.\",\"authors\":\"Saad O Atiq, Matthew D Galsky\",\"doi\":\"10.1016/j.euf.2025.06.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Treatment decisions for patients with upper tract urothelial carcinoma (UTUC) require individualized assessments that weigh tumor characteristics, patient factors, and the evidence available. Adjuvant immune checkpoint blockade represents a significant advance in UTUC management, particularly for patients who are ineligible for cisplatin and those with residual disease after neoadjuvant therapy.\",\"PeriodicalId\":12160,\"journal\":{\"name\":\"European urology focus\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-07-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology focus\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.euf.2025.06.013\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology focus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euf.2025.06.013","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

上路尿路上皮癌（UTUC）患者的治疗决策需要个性化评估，权衡肿瘤特征、患者因素和现有证据。辅助免疫检查点阻断代表了UTUC管理的重大进步，特别是对于那些不适合顺铂治疗和新辅助治疗后残留疾病的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Evolving Treatment Paradigm for Upper Tract Urothelial Carcinoma.

Treatment decisions for patients with upper tract urothelial carcinoma (UTUC) require individualized assessments that weigh tumor characteristics, patient factors, and the evidence available. Adjuvant immune checkpoint blockade represents a significant advance in UTUC management, particularly for patients who are ineligible for cisplatin and those with residual disease after neoadjuvant therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European urology focus Medicine-Urology

CiteScore

10.40

自引率

3.70%

发文量

274

审稿时长

23 days

期刊介绍： European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU). EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.